AI trends and adoption in Life Sciences

Here's what's in this month's newsletter:

• NyquistAI Insights: Global data and intelligence from our platform
• New Website!:?Welcome to the next chapter of NyquistAI
• Use Case Spotlight: Analyzing clinical trial protocols
• This Month in AI, MedTech, & Biopharma: AI trends and adoption in Life Sciences

Nyquist Insights

Q1 2024 insights from the NyquistAI data platform

To gain further insights like these and discover the full potential of our platform, schedule an introductory meeting with one of our product experts to learn more.

SCHEDULE AN INTRO CALL!

Use Case Spotlight

Effortless Analysis of Competitor Clinical Study Protocols

• PAIN POINTS: Clinical Trial Design, Competitive Intel, Clinical Study Protocol
• VERTICALS: Manufacturers, CROs
• FUNCTIONAL AREAS: Competitive Intel, Clinical Strategy, Clinical Operations

PROBLEM

Analyzing competitors' clinical trials and clinical study protocols is a time consuming, manual task. It requires analysts or consultants to read lengthy documents, which makes quick insights and trend analysis difficult.

SOLUTION

With NyquistAI’s Global Trial Database, finding competitor clinical study protocols is just a click away. By adding the analytical power of NyquistIQ, our AI can answer any questions you have about an individual protocol or look for trends (or outliers) among a predefined set of protocols.

VALUE

Reduce the time and cost associated with conducting this crucial competitive intelligence. Provide your clinical strategy and clinical operations teams with better and more comprehensive insights, paving the way for more successful trials!

Welcome to the Next Chapter of NyquistAI!

We're excited to unveil NyquistAI's latest online presence – a brand new website showcasing solutions that harness the incredible potential of artificial intelligence to drive change in the dynamic realm of life sciences.

Embracing AI for Transformation

At NyquistAI, we're committed to leveraging AI technologies thoughtfully and purposefully. Our revamped website highlights how we're revolutionizing data utilization within the life sciences industry. Through our advanced AI solutions, we're empowering professionals with intuitive, PhD-level research assistance.

Empowering Progress and Innovation

Explore our comprehensive suite of offerings meticulously crafted to address the pressing challenges faced by professionals in the life sciences sector. From cutting-edge research tools to innovative data analysis, we're driving progress and fostering innovation at every turn.

Discover and Shape the Future Today

We invite you to navigate through our refreshed website and experience firsthand how NyquistAI is redefining possibilities within the industry through the seamless fusion of data and intelligence.

Visit our newly launched website today and embark on a journey towards innovation, discovery, and unparalleled success!

THIS MONTH IN AI, MEDTECH, & BIOPHARMA

5 Trends Shaping the Life Sciences Industry in 2024

The life sciences industry is driven by innovation, constantly reshaping global health. Amidst daily breakthroughs, it's challenging to predict which trends will shape the year ahead. Despite setbacks like a slump in biotech investments and regulatory uncertainties in 2023, there were significant triumphs, showcasing the industry's resilience.

Looking ahead, drawing insights from an article by peoplewithchemistry.com and Deloitte's 2024 Health Care and Life Sciences Outlook, here are five trends are anticipated to redefine the industry:

1. Focus on Obesity and Metabolic Drugs: Obesity is recognized as a chronic disorder, driving demand for personalized treatments. Clinical evidence supports the cardiovascular benefits of new obesity treatments, leading to a surge in research and development. NyquistAI Insight: Currently there are 56 drugs with "Obesity" in the indication in the NyquistAI Data Platform including 25 in China, 53 in the US, and 27 in the EU.
2. Integration of AI and Machine Learning: AI has become standard in life sciences, impacting drug discovery, clinical development, and more. Deloitte's outlook highlights its anticipated influence on automating functions and regulatory compliance.
3. Attention to Health Equity: Efforts to address health disparities are gaining momentum, driven by both moral and strategic imperatives. Companies are investing in diverse data gathering and inclusive clinical trials to develop more equitable products and services.
4. CRISPR Technology in Cell and Gene Therapies: CRISPR technology, exemplified by Casgevy's approval for sickle cell disease, is revolutionizing genetic disorder treatments. A wave of research and development is expected, promising more effective and accessible therapies. NyquistAI Insight: Currently there are 103 active clinical trials in the NyquistAI Data Platform that reference CRISPR.
5. Advancements in Oncology: The oncology sector is witnessing progress in immunotherapies, targeted therapies, and personalized vaccines. Genomic profiling and molecular diagnostics are enabling tailored treatment strategies, with hopes of further reducing cancer mortality rates.

2024 holds promise for transformative trends in life sciences, paving the way for more effective, accessible, and personalized healthcare. Innovation remains key, driving the industry forward towards a future where each patient's needs are met with precision.

Click HERE to read the full article.?

Unlocking the Potential: Leaders in AI Adoption

In a world where innovation drives progress, the transformative power of artificial intelligence (AI) is reshaping industries at an unprecedented pace. According to a recent McKinsey article, leaders in AI adoption are poised to witness the benefits of scale, particularly in the realm of MedTech.

• Gen AI in Medtech: Foundational models of generative AI (gen AI) are revolutionizing medtech, with applications in product development, digital-twin technologies, and insight-generating tasks.
• Productivity Gains: Companies embracing gen AI are witnessing productivity benefits, starting with assisting workers in HR, IT, finance, and legal roles.
• Exploring New Frontiers: Gen AI is poised to transform commercial and operational roles in medtech, with opportunities in areas such as supply chain management and user experience enhancement.
• Regulatory Landscape: While deep integration of AI in medical products awaits regulatory clearance, early adopters are laying the groundwork for future innovations.
• Global Approvals: Regulatory bodies like the US FDA and China NMPA are increasingly approving AI devices, reflecting the growing momentum in AI adoption. NyquistAI Insight: In Q1 2024 we saw new AI devices approved globally, including 35 added in US FDA and 6 added in China NMPA.

At NyquistAI, we're committed to tracking the latest developments in AI adoption, empowering companies to leverage gen AI for transformative impact in medtech and beyond.

Click HERE to read the full article by McKinsey.

Come See Us at These Events!

• DeviceTalks Boston - May 1-2 (Boston,MA)
• Medical Alley Annual Dinner - May 16 (Minneapolis, MN)
• BIO 2024 - June 3-6 (San Diego, CA)
• WSGR 2024 - June 13-14 (San Francisco, CA)

Interested to see how NyquistAI can give you a competitive advantage in 2024?

Contact Us Today!